SSG
CTKB icon

Summit Securities Group’s Cytek Biosciences CTKB Stock Holding History

Summit Securities Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,704
Closed -$7.45K – 1201
2026
Q1 		$7.45K Buy
+1,704
New +$8.04K ﹤0.01% 719
2025
Q3 		– Sell
-33,276
Closed -$113K – 1090
2025
Q2 		$113K Buy
+33,276
New +$111K 0.02% 345
2024
Q3 		– Sell
-878
Closed -$5K – 636
2024
Q2 		$5K Buy
+878
New +$5.27K ﹤0.01% 489

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Summit Securities Group's CTKB Position: Q2 2026 in Review

Summit Securities Group sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 1,704 shares — an estimated $7.45K sold.

Summit Securities Group first reported a position in CTKB in Q2 2024 and held it in 3 quarters. The position peaked at $113K in Q2 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Summit Securities Group reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 1,704 Cytek Biosciences shares in Q2 2026, an estimated $7.45K.
  • Summit Securities Group first reported a position in Cytek Biosciences in Q2 2024 and held it in 3 quarters.
  • Summit Securities Group's Cytek Biosciences position peaked at $113K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.